These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 29691664)
1. Characterization of the PEGylated Functional Upstream Domain Peptide (PEG-FUD): a Potent Fibronectin Assembly Inhibitor with Potential as an Anti-Fibrotic Therapeutic. Zbyszynski P; Tomasini-Johansson BR; Peters DM; Kwon GS Pharm Res; 2018 Apr; 35(7):126. PubMed ID: 29691664 [TBL] [Abstract][Full Text] [Related]
2. PEGylated pUR4/FUD peptide inhibitor of fibronectin fibrillogenesis decreases fibrosis in murine Unilateral Ureteral Obstruction model of kidney disease. Tomasini-Johansson BR; Zbyszynski PW; Toraason I; Peters DM; Kwon GS PLoS One; 2018; 13(10):e0205360. PubMed ID: 30356276 [TBL] [Abstract][Full Text] [Related]
3. Probing the subcutaneous absorption of a PEGylated FUD peptide nanomedicine via in vivo fluorescence imaging. Zbyszynski P; Toraason I; Repp L; Kwon GS Nano Converg; 2019 Jul; 6(1):22. PubMed ID: 31281949 [TBL] [Abstract][Full Text] [Related]
4. Multimodal imaging demonstrates enhanced tumor exposure of PEGylated FUD peptide in breast cancer. Lee HJ; Gari MK; Inman DR; Rosenkrans ZT; Burkel BM; Olson AP; Engle JW; Hernandez R; Ponik SM; Kwon GS J Control Release; 2022 Oct; 350():284-297. PubMed ID: 35995299 [TBL] [Abstract][Full Text] [Related]
5. Fibronectin-targeted FUD and PEGylated FUD peptides for fibrotic diseases. Lee HJ; Tomasini-Johansson BR; Gupta N; Kwon GS J Control Release; 2023 Aug; 360():69-81. PubMed ID: 37315694 [TBL] [Abstract][Full Text] [Related]
6. PEGylation of cholecystokinin prolongs its anorectic effect in rats. León-Tamariz F; Verbaeys I; Van Boven M; De Cuyper M; Buyse J; Clynen E; Cokelaere M Peptides; 2007 May; 28(5):1003-11. PubMed ID: 17379357 [TBL] [Abstract][Full Text] [Related]
8. Extended binding site on fibronectin for the functional upstream domain of protein F1 of Streptococcus pyogenes. Maurer LM; Tomasini-Johansson BR; Ma W; Annis DS; Eickstaedt NL; Ensenberger MG; Satyshur KA; Mosher DF J Biol Chem; 2010 Dec; 285(52):41087-99. PubMed ID: 20947497 [TBL] [Abstract][Full Text] [Related]
9. Disruption of fibronectin matrix affects type IV collagen, fibrillin and laminin deposition into extracellular matrix of human trabecular meshwork (HTM) cells. Filla MS; Dimeo KD; Tong T; Peters DM Exp Eye Res; 2017 Dec; 165():7-19. PubMed ID: 28860021 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Lee SH; Lee S; Youn YS; Na DH; Chae SY; Byun Y; Lee KC Bioconjug Chem; 2005; 16(2):377-82. PubMed ID: 15769092 [TBL] [Abstract][Full Text] [Related]
14. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties. Däpp S; García Garayoa E; Maes V; Brans L; Tourwé DA; Müller C; Schibli R Nucl Med Biol; 2011 Oct; 38(7):997-1009. PubMed ID: 21982571 [TBL] [Abstract][Full Text] [Related]
15. Reproducible production of a PEGylated dual-acting peptide for diabetes. Tom I; Lee V; Dumas M; Madanat M; Ouyang J; Severs J; Andersen J; Buxton JM; Whelan JP; Pan CQ AAPS J; 2007 Jun; 9(2):E227-34. PubMed ID: 17907763 [TBL] [Abstract][Full Text] [Related]
16. Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycol-modified growth hormone-releasing factor (1-29). Youn YS; Na DH; Yoo SD; Song SC; Lee KC J Chromatogr A; 2004 Dec; 1061(1):45-9. PubMed ID: 15633743 [TBL] [Abstract][Full Text] [Related]
17. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals. Natarajan A; Xiong CY; Albrecht H; DeNardo GL; DeNardo SJ Bioconjug Chem; 2005; 16(1):113-21. PubMed ID: 15656582 [TBL] [Abstract][Full Text] [Related]
18. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199 [TBL] [Abstract][Full Text] [Related]
19. Toward top-down determination of PEGylation site using MALDI in-source decay MS analysis. Yoo C; Suckau D; Sauerland V; Ronk M; Ma M J Am Soc Mass Spectrom; 2009 Feb; 20(2):326-33. PubMed ID: 19019698 [TBL] [Abstract][Full Text] [Related]